Abstract
Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and “non-antimicrobial” pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field.
Keywords: Corticosteroids, efflux pump inhibitors, microenvironment, inflammation, TNF-α.
Current Molecular Medicine
Title:Novel Adjunctive Therapies for the Treatment of Tuberculosis
Volume: 14 Issue: 3
Author(s): A.A. Ordonez, M. Maiga, S. Gupta, E.A. Weinstein, W.R. Bishai and S.K. Jain
Affiliation:
Keywords: Corticosteroids, efflux pump inhibitors, microenvironment, inflammation, TNF-α.
Abstract: Despite significant efforts to control tuberculosis (TB), the disease remains a major global threat, with an estimated 8.6 million new cases and 1.3 million deaths in 2012 alone. Significant treatment challenges include HIV co-infection, the dramatic rise of multidrug-resistant TB and the vast reservoir of latently infected individuals, who will develop active disease years after the initial infection. The long duration of chemotherapy also remains a major barrier to effective large scale treatment of TB. Significant advances are being made in the development of shorter and effective TB drug regimens and there is growing evidence that host-directed and “non-antimicrobial” pathogen-directed therapies, could serve as novel approaches to enhance TB treatments. This review highlights the rationale for using these therapies and summarizes some of the progress in this field.
Export Options
About this article
Cite this article as:
Ordonez A.A., Maiga M., Gupta S., Weinstein E.A., Bishai W.R. and Jain S.K., Novel Adjunctive Therapies for the Treatment of Tuberculosis, Current Molecular Medicine 2014; 14 (3) . https://dx.doi.org/10.2174/1566524013666131118112431
DOI https://dx.doi.org/10.2174/1566524013666131118112431 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vascular Endothelial Growth Factor (VEGF) in Pleural Effusions
Current Enzyme Inhibition Meet Our Editorial Board Member:
Current Medicinal Chemistry Internet Resources for Drug Discovery and Design
Current Topics in Medicinal Chemistry Molecules of Infectious Agents as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Tuberculosis of the Thymus: A Case Report and Review of the Literature
Current Respiratory Medicine Reviews Management of Tuberculosis in Children and New Treatment Options
Infectious Disorders - Drug Targets Editorial (Thematic Issue: Tropical Rheumatology)
Current Rheumatology Reviews Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection
Current Pharmaceutical Design Managing Febrile Illness in Malaria-endemic Areas: Developing Novel Diagnostics Using Host Immunological Signatures as Surrogate Markers of Infection
Current Immunology Reviews (Discontinued) The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Signalling Inhibitors Against Mycobacterium tuberculosis – Early Days of a New Therapeutic Concept in Tuberculosis
Current Medicinal Chemistry Commercially Available, FDA-approved Epigenetic Modifiers As Therapeutic Agents in Bacterial Infection
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery Analysis of Wild-Type and Gly96Ala Mutant EPSP Synthase Structures via in Silico Docking with Inhibitors and Molecular Dynamics Simulation
Current Bioactive Compounds Mannose Binding Lectin: A Potential Biomarker for Many Human Diseases
Current Medicinal Chemistry Phytochemical Content and Potential Health Applications of Pecan [<i>Carya illinoinensis</i> (Wangenh) K. Koch] Nutshell
Current Topics in Medicinal Chemistry QSAR Studies, Synthesis and Antibacterial Assessment of New Inhibitors Against Multidrug-Resistant Mycobacterium tuberculosis
Current Drug Discovery Technologies